Important progress has been made with the development of both surgical and medicinal treatment of epilepsy but these two developments are rarely seen in a common perspective. Today epilepsy surgery should be discussed with the patient when a reasonable degree of pharmacoresistance has been established, and the chances of an operation clearly outweigh its risks. At that time, there will still be a number of pharmacological options.
INTRODUCTION
Epilepsy surgery, although a suitable approach for only a minority of patients, has, during the last decade, appeared to many as the most important frontier in epileptology. This view, however, has been radically contested in this journal'. At the same time, we are experiencing the advent of a considerable number of new antiepileptic drugs with a diversity of mechanisms of action which are introduced with high hopes for therapeutic improvements. In patients whose seizures are resistant to traditional drugs they seem, however, only rarely to provide complete seizure control, the ultimate aim of epilepsy therapy.
These developments are rarely seen together in a common perspective. There are wide discrepancies in the approach to new developments in these two therapeutic fields, for example, in the role accorded to randomized controlled trials'. In addition, neither of these strategies seem to take any notice of alternative, non-drug non-surgery approaches2-5. We should be concerned with the possibility that the various strategies of epilepsy treatment drift apart to form separate therapeutic culturescertainly not a development in the patients' interest.
Another concern is that epilepsy surgery is often regarded as a last hope for therapy-resistant patients with epilepsy, and a frequent concern of people who care about such patients is what may happen if that hope also fails. It should be recalled, however, that there is no absolute and ultimate therapy resistance, and the number of possible therapeutic strategies is increasing with the advent of new drugs. Today, epilepsy surgery is not considered when no pharmaceutical option whatsoever is open but when standard pharmacotherapy has failed, and chances of finding a successful conservative treatment6 are small.
There is no universally accepted guideline about the extent of pharmacoresistance which should be reached before considering surgery. In particular, there is no consensus about the role of the new AEDs in this respect, or of the usefulness of trying drug combinations before going to surgery. Most of the centres performing epilepsy surgery therefore seem to follow their own policy, and it has not even become routine yet-as would be desirable-for the centres to publish their criteria. At our centre we request that three first-choice antiepileptic drugs (AEDs) should have been administered, in monotherapy, in doses increasing until first toxic side-effects appeared, and did not control the seizures, at least not those seizures which are disabling or a challenge to the patients' quality of life7. Usually, in that case, the possibility of epilepsy surgery will be discussed, and presurgical intensive monitoring will be proposed. However, not all of these patients will accept this suggestion. Some are strictly opposed to the idea of brain surgery, others will first ask for further drug trials, and still others will accept intensive monitoring on the expressed condition that the ultimate decision will only be taken afterwards. The above selection process ensures that there will still be pharmacotherapeutic options in the case where surgery is declined following intensive monitoring.
In that case, there are again no guidelines for therapy, and there are to my knowledge no reports of patients in that situation. This paper is a report of those 15 patients who have been under the authors treatment for a period of at least four years after epilepsy surgery was first considered, and then rejected. The idea of presenting this small series is not to promote or establish any therapeutic strategies and guidelines but, rather, to draw attention to a neglected interface between surgical and medicinal procedures, and to increase awareness that epilepsy therapy will still be most successful when it is seen as a whole, and must not be split up into competing ideologies.
PATIENTS AND METHODS
The demographic and diagnostic data are summarized in Table 1 . All patients had focal (partial onset) seizures. All underwent some type of non-invasive or invasive intensive EEG monitoring in view of possible epilepsy surgery (Table 2 ). These investigations took place between April 1987 and March 1992, and the patients have prospectively been followed since then. In two instances, the evaluation was done elsewhere, and I first met the patients afterwards. All others were in my treatment before, and intensive monitoring had been decided between us following failure of pharmacotherapy. All but one of the latter 13 evaluations were performed in our centre. Noncompliance as a reason for pharmacoresistance had been ruled out in all 15 cases by post-ictal assessments of AED serum levels.
In six cases, invasive further studies, and in another six, a surgical intervention had been discussed with the patients whereas, in the remaining three, the results of the evaluation had discouraged any further steps. Further procedures were declined at least temporarily by the patients and their relatives in seven cases and by the hospital team in six cases, with two immediate consensus decisions (Table 2) . No uniform treatment plan was followed as previous investigations suggested taking individually different routes. The primary therapeutic aim was still to render the patients free of all, or at least of all disabling, seizures.
All seizures were documented in a seizure calendar differentiating between seizure types. Patients were usually seen in intervals of 3 months. Serum AED levels were determined for three reasons: to establish the individual pharmacokinetics of a given drug, to prove or refute possible toxicity, and following unexpected seizures to check for compliance problems and establish the individual therapeutic threshold. All other tests were done according to clinical necessity.
As these are patients who had been considered for epilepsy surgery, it seems instructive to analyse them according to the scale which is most frequently used for the outcome measurement of operated patients'. This was slightly modified to meet the requirements of assessing people not surgically treated (Table 3) . Epilepsy treatment after surgery rejection 27 
RESULTS
The results are given in Table 4 where the patients are assigned to an outcome group according to the 12 months preceding the last contact. Of the 15 patients, four (26.7%) belong to outcome group I as three are completely seizure free (IA), and one has no convulsive seizures but only isolated auras (IB). One patient is in outcome group II (rare minimal focal seizures), and three are in group III, whereas seven patients (46.7%) are in group IV (one with moderate seizure reduction, and six unchanged). Of the unimproved patients, one has eventually accepted the proposed temporal lobectomy which was only partly successful (group IIIA with CP seizures in sleep, and isolated auras in the wake state). The case histories of the four patients in outcome group I are given below.
(1) PF, a 50 year old housewife presented with simple focal sensorimotor seizures of the left face and arm, sometimes evolving to generalized tonic-clonic (GTC) seizures. These had started during an acute febrile illness at age 45 (suspected encephalitis) and did not respond to monotherapies of phenytoin (DPH, intolerable side-effects reported at plasma level 18.2 pg ml-'), carbamazepine (CBZ, 11.6 @g ml-') and phenobarbital (PB, 34.0 p.g ml-'). The reported side-effects were rather uncharacteristic, and the low tolerance seemed to suggest problems of coping with the illness. At non-invasive intensive monitoring several habitual focal seizures were recorded and were in favour of a right perirolandic origin. Semi-invasive monitoring with epidural peg electrodes was suggested as a next step of evaluation. For the first time, the patient realized the seriousness of the illness, spontaneously increased her phenobarbital dose from 150 to 200 mg per day, and became seizure free at plasma levels of 40-45 pug ml-' which were now well tolerated. Three years after the last seizure, dose reduction began, and the patient remained seizure free with a PB level of 28.6 p.g ml-' at a daily dose of 130 mg.
(2) RL, a 49 year old deacon, developed cryptogenie epilepsy with both generalized and focal features at age 21. His seizure types were complex partial (CP), generalized clonic, and GTC. He had never received monotherapy but was treated with changing combinations of DPH, PB, primidone (PRM), CBZ, valproic acid (VPA) and clobazam (CLB). He was considered drug resistant, and had intensive monitoring at a well-known centre for epilepsy surgery. A combination of foramen ovale and scalp electrodes revealed ictal onset with bilaterally symmetric Poly-Spike-Waves. It was proposed to try vigabatrine (VGB) and lamotrigine (LTG), and, in case of failure, consider callosotomy. When I first saw him, both VGB and LTG had in turn been unsuccessfully added to a combination of PRM and CBZ. Detailed scrutiny of his case records revealed that, at an early stage, he had been seizure free for several years with a four- drug combination of which all components but VPA had later unsuccessfully been used again. VPA was added to his baseline medication, and he has now been seizure free for more than 3 years. (3) JA, a 50 year old auctioneer had cryptogenie temporal lobe epilepsy since age 10, with CP seizures of increasing duration and complex automatisms. He was resistant to CBZ (16.0 pug ml-'), DPH (25.3 pg ml-') and add-on medications of PB (22.5 pg ml-') and mesuximide (MS, 32.5 ,ug ml-').
Non-invasive intensive monitoring revealed bilateral temporal interictal and ictal epileptic foci, and PET scanning demonstrated massive bitemporal hypometabolism. The surgical indication was therefore considered to be highly problematic, and further drug trials recommended. Addition of VGB to a previous DPH monotherapy led to a drastic fall in seizure frequency. DPH was slowly withdrawn, and the patient became practically seizure free on VGB monotherapy. In 2 years, he has only had one cluster of SP and CP seizures at 4 g/day, and a single isolated aura at 5 g/day which he tolerates well. He has been completely seizure free for more than 12 months.
(4) UW, a 40 year old housewife, suffered from focal epilepsy since a right frontopolar haemorrhage from an angioma at age 32. Her seizure types were isolated auras with an illusion of movement, and secondarily generalized TC seizures with an initial version and elevation of her left arm, resulting in a habitual shoulder luxation. She was resistant to CBZ (12.4 kg ml-'), DPH (45.4 kg ml-') and a PB add-on therapy (31.0 pg ml-'). Two phases of noninvasive intensive monitoring gave no clues about the focus localization during the recorded isolated auras. No proposal for further procedures could be made. VGB was added to her regimen without effect, and withdrawn. Bromide was added, and her GTC seizures stopped. She is now on bromide monotherapy with serum levels of 1.0-1.2 mg ml-' and has had no GTC seizures for the last 3 years. She has fre- quent isolated auras which, however, she can easily cope with. When outcome classes I-III are considered together as 'successful' (n = 8) as opposed to unsuccessful (group IV, 12 = 7) therapies, it transpires that the successful regimens comprise such diverse concepts as monotherapies with high-level phenobarbital, vigabatrine, and, of all things, bromide (an excellent drug for pharmacoresistant GTCS9), two two-drug, two threedrug and one four-drug combinations (Table 5 ). A total of nine different drugs were used on these eight patients without any unacceptable side-effects.
A comparison of outcomes and types of epilepsy (Table 6) seems to indicate that patients with temporal lobe epilepsy could be less successfully treated (i) than those with extratemporal epilepsies (i) or both focal and generalized features (i). The only case of clearly bitemporal epilepsy, however, made a very good outcome, and the apparent differences may be due to the small number of patients.
The outcome of therapeutic interventions should not only refer to seizure control but also to quality of life. The relatively satisfactory pattern of employment, even of the unsuccessfully treated patients of this group (Table 7) , reflects the rehabilitation activities of the providing epilepsy centre. Of the four patients with an unsatisfactory vocational status ('early pension' or 'involuntary housewife'), three are therapy resistant, and the one with successful treatment (case (3)) went into early retirement as a consequence of his seizures, before the successful therapy was found.
DISCUSSION
When the seizures of a patient with focal epilepsy resist treatment with a suitable drug of first choice, the Epilepsy treatment after surgery rejection chances of obtaining seizure control with a change to another drug or a combination of two AEDs are in the order of lO-20% each",". Newly developed drugs at best make a similar addition to the rate of patients with complete seizure control. In most centres, epilepsy surgery is today discussed after failure of two to three appropriate AEDs because, then, the chances of therapy success are much higher with surgery than with pharmacotherapy, provided that the patients are properly selected. Thus, epilepsy surgery is not a 'last hope' for otherwise intractable patients as is sometimes suggested. It rather presents the patient with a promising therapeutic alternative when the chances of relief from seizures by pharmacotherapy have become small and the further pursuit of pharmacological options must be expected to be time consuming and of uncertain outcome.
In that situation, some patients will all the same prefer to continue with pharmacotherapy, and those who decide for a presurgical evaluation should know that, if no indication for surgery results, further pharmaceutical options exist. Until now, however, it is not possible to numerically specify the chances of such therapy if it comprises a whole sequence of treatments with drugs of second choice and variable AED combinations.
The number of patients in this study is too small to provide reliable figures. One of the purposes of this paper is to draw attention to this problem and stimulate more extensive research. The value of the study is in the fact that all patients have been treated by one epileptologist, in all but two cases both before and following a presurgical evaluation after which the surgical option was not pursued. In all but the stated two cases, the strictest criteria of AED resistance presently in use were fulfilled before the presurgical evaluation. With regard to seizure types, focus localization and aetiologies, the patient group is fairly typical for the selection of patients monitored in our, and probably many other, centres.
The outcome of conservative treatment in this small sample may not be representative, and too optimistic. A few conclusions, however, may be drawn.
(1) Pharmacoresistance is not an absolute but a relative concept. (2) There is probably no standard therapy for patients with focal epilepsies and a relatively high degree of pharmacoresistance. Often, individ-29 ual strategies need to be developed which may prove highly rewarding. It can be useful to develop them on the background of earlier relative therapeutic successes in the same patient. (3) Complex empirical AED combinations are permissible therapies provided they are successful, and appropriate monotherapies have previously been tried. (4) Older and second-line drugs are by no means second-rate or obsolete. In the individual case, they may be more successful than first-line drugs. (5) The new AEDs will not solve all or most of the remaining problems of pharmacoresistance; they will, however, contribute to solve some. (6) A satisfactory vocational status as a measure of the quality of life does not necessarily depend upon a good therapeutic outcome, but seizure control is helpful.
